stockrow
Friday 6 November 2026
Export UFPT’s income statement to Excel — free account
UFP Technologies, Inc.
UFPT Healthcare Medical Devices
UFP Technologies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $602.8 million, up 19.5% from fiscal 2024.
- Revenue
- +11.6%
- EPS
- +25.6%
- Free cash flow
- −35.8%
- Total debt
- −40.2%
Quarter to September 2026, against a year earlier
302.33
2.51
+0.84%
Follow UFPT
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
25.03 | 21.75 | 28.33 | 29.98 |
P/S ratio |
2.84 | 2.46 | 3.25 | 3.54 | |
P/FCF ratio |
21.65 | 21.49 | 33.37 | 37.38 | |
P/Operating CF |
101.59 | 466.54 | 131.44 | 147.27 | |
P/B ratio |
4.04 | 3.41 | 4.44 | 4.97 | |
Price to Tangible BV |
19.98 | 14.32 | 15.70 | 18.05 | |
EV/Sales |
3.05 | 2.67 | 3.44 | 3.66 | |
EV/EBITDA |
16.50 | 14.52 | 18.75 | 20.47 | |
EV/Operating CF |
20.02 | 20.00 | 30.38 | 33.17 | |
EV/FCF |
23.28 | 23.38 | 35.36 | 38.61 | |
Quick Ratio |
1.45 | 1.59 | 1.61 | 1.52 | |
Current Ratio |
2.69 | 2.91 | 3.00 | 2.98 | |
Net Debt/EBITDA |
4.89 | 4.64 | 3.71 | 0.00 | |
Debt/Assets |
22.81% | 22.39% | 19.30% | 14.06% | |
Debt/Equity |
0.35 | 0.34 | 0.28 | 0.20 | |
Asset Turnover |
0.94 | 0.92 | 0.96 | 0.97 | |
Operating CF/Net income |
0.96 | 0.18 | 0.75 | 0.00 | |
Capex/Depreciation |
(0.78) | (0.34) | (0.23) | — | |
Interest Coverage |
11.14 | 13.45 | 16.42 | 18.50 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
14.08% | 13.63% | 13.08% | 13.43% | |
Intangible Assets out of Total Assets |
0.52 | 0.50 | 0.49 | 0.49 | |
Share Based Compensation of Revenue |
1.61% | 1.77% | 1.85% | 0.00% | |
Graham Net Nets |
(0.02) | (0.01) | 0.01 | 0.01 | |
Graham Number |
104.78 | 106.69 | 112.17 | 0.00 | |
Earnings Yield |
3.99% | 4.60% | 3.53% | 3.34% | |
Free Cash Flow Yield |
4.62% | 4.65% | 3.00% | 2.67% | |
Revenue per Share |
19.33 | 19.97 | 22.48 | 22.26 | |
Operating CF per Share |
2.19 | 0.42 | 2.02 | 0.00 | |
Capex per Share |
(0.50) | (0.22) | (0.15) | 0.00 | |
Free Cash Flow per Share |
1.69 | 0.20 | 1.87 | 0.00 | |
Cash per Share |
2.63 | 2.59 | 1.17 | 2.66 | |
Shareholders Equity per Share |
55.01 | 56.84 | 59.74 | 62.71 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
55.01 | 56.84 | 59.74 | 62.71 | |
Free Cash Flow |
12.98 | 1.52 | 14.46 | — | |
Working Capital |
126.14 | 147.09 | 156.59 | 153.28 | |
Capital Expenditures |
(3.86) | (1.69) | (1.15) | — | |
Net Current Asset Value |
(30.20) | (11.70) | 15.41 | 33.72 | |
EV/EBIT |
19.93 | 17.56 | 22.57 | 23.61 | |
Capex to Sales |
0.03 | 0.01 | 0.01 | 0.00 | |
Price to Operating Income |
18.53 | 16.15 | 21.30 | 22.86 | |
| Other line items | |||||
Average Receivables |
88.94 | 99.74 | 102.00 | 92.07 | |
Average Payables |
24.28 | 29.07 | 27.81 | 27.97 | |
Average Inventory |
87.20 | 91.91 | 92.65 | 92.15 | |
Average Assets |
642.04 | 658.66 | 658.28 | 667.73 | |
Average Common Equity |
383.32 | 399.77 | 423.96 | — |
Columns are period end dates · fundamentals updated 5 Nov 2026